A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost.
Rheumatoid arthritis (RA) is a chronic auto-immune disease that causes pain and stiffness in the joints, fatigue, bone damage and, eventually, loss of mobility. RA afflicts around 1% of people in the western world; in Belgium, 80,000 to 100,000 people currently live with the disease.
Because there is no known cure for RA, physicians focus treatment on suppressing disease activity. Therapies have improved in recent years, and clinical studies show that intensive treatment of early RA can prevent joint damage and improve patients’ quality of life.
In the two-year study, called ‘CareRA’ (Care in early RA), researchers and clinicians in the rheumatology unit at University Hospitals Leuven examined various therapies for early RA. Their goal: to find the optimal combination and dosage of three commonly prescribed antirheumatic drugs (methotrexate, sulfasalazine and leflunomide) in combination with glucocorticoids (a class of steroid hormones).
The researchers divided 290 early RA patients into three treatment groups. Each group received a different combination therapy: ‘COBRA Classic’ (methotrexate, sulfasalazine and a high first dose of glucocorticoids), ‘COBRA Slim’ (methotrexate and a moderate dose of glucocorticoids) or ‘COBRA Avant-Garde’ (methotrexate, leflunomide and a moderate dose of glucocorticoids).
Fewer side effects
All three strategies showed a similarly high efficacy: disease remission was achieved in 7 in 10 patients after 16 weeks of treatment. But results for the strategies varied significantly when it came to side effects.
The new COBRA Slim strategy, which calls for the least amount of medication, had half as many side effects as the two other strategies – and was just as effective. The strategy would also be easier to implement in daily practice because it is less complicated.
A broader use of this strategy would lead to higher remission rates in the global early RA population and would probably reduce the need for expensive second-line antirheumatic treatment, say the researchers.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- Navidea imaging agent shows predictive value in rheumatoid arthritison November 12, 2020 at 1:24 pm
Navidea Biopharmaceuticals (NYSEMKT:NAVB) announces encouraging data from the third arm in a Phase 2b clinical trial evaluating imaging agent Tc99m tilmanocept in patients with active rheumatoid ...
- Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritison November 12, 2020 at 1:05 pm
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to ann ...
- Scientists pinpoint two new potential therapeutic targets for rheumatoid arthritison November 12, 2020 at 12:31 pm
A collaborative team of scientists has pinpointed two new potential therapeutic targets for rheumatoid arthritis—a painful inflammatory disease that affects an estimated 350 million people worldwide.
- New Medication Guidelines for Treating Rheumatoid Arthritis Previewedon November 12, 2020 at 11:26 am
The latest guidance on treating rheumatoid arthritis with drugs were presented at ACR 2020, the annual meeting of the American Rheumatology College. Learn how the guidelines have changed since 2015.
- Rheumatoid arthritis may increase risk of dying from COVID-19on November 11, 2020 at 4:06 pm
Researchers in New Zealand and Australia have conducted a study showing that people with rheumatoid arthritis may be at an increased risk of death if they develop coronavirus disease 2019 (COVID-19) ...
- New Data Show Importance of Vectra(R) Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritison November 11, 2020 at 1:33 pm
(NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, shared new data further demonstrating that Vectra testing and three additional biomarkers, combined with traditional risk ...
- Rheumatoid Arthritis (RA) Pipeline Insight Report 2020 Featuring 10 Key Players & 12 Products - ResearchAndMarkets.comon November 11, 2020 at 4:38 am
Pipeline Insight, 2020” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Rheumatoid Arthritis pipeline landsca ...
- New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritison November 11, 2020 at 4:11 am
(NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, shared new data further demonstrating that Vectra ® testing and three additional biomarkers, combined with traditional risk ...
- SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritison November 8, 2020 at 10:04 pm
The Data Safety Monitoring Board (DSMB) finds no safety concerns in the 50 mg and 100 mg dose cohorts Signs of efficacy against rheumatoid arthritis ...
- Global Rheumatoid Arthritis (RA) Drugs Market 2020 Production, Revenue, Growth Rate, Price and Gross Margin, Opportunities and Forecast 2026on November 8, 2020 at 8:24 pm
Drugs Industry research report includes the future impact of major drivers and challenges and, support decision makers in manufacture cost-effective professional decisions. According to Investigator ...
via Bing News